InvestorsHub Logo
Followers 8
Posts 1891
Boards Moderated 0
Alias Born 05/05/2016

Re: Auto1 post# 17208

Monday, 10/22/2018 11:31:02 AM

Monday, October 22, 2018 11:31:02 AM

Post# of 44784

Must be why the orders wont stop coming in!! This is what happens when you make your bookeeper your top salesman.

Rather than sarcasm, I would like to see a detailed criticism of Mr.Yanay's visionary plans (see below) for Pluristem! Any particular part that "Auto1" finds "bookeeperish"??? Seems like management has a very plausible and very exciting plan for the (near) future.



“It’s a good time for us to start to discuss with governments their need to start stockpiling in their countries,” Yanay explains. “We are telling them, if you want to make sure we are keeping an inventory for you, go ahead and place an order for this product.”

After more than a decade of research and trials of its groundbreaking placenta-based regenerative medicine, Pluristem is ready to move to the next level. “I’m preparing our company toward marketing,” says Yanay.

The company has a “three-leg strategy” for its commercialization.

1. Its products for muscle regeneration and treating CLI, once approved, will be distributed under license and partnership agreements with large pharmaceutical companies, and

2. its radiation exposure treatments will be sold directly to governments.

3. The third leg, based on Pluristem’s hematological and oncology division, will develop its own premium products and marketing capability.

“We are one of the very few companies in the world that control our entire process,” Yanay says. “We decided to invest in infrastructure and technology in order to be able to manage the entire spectrum, from the placenta to the patient’s bed, and hopefully become one of the major players in the industry.”

This is the start of an exciting journey that has the very real possibility of being a fundamental, game-changing breakthrough in healthcare.